Orchid Pharma Limited
Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs.
What Orchid files
- Others47
- Investor Meet27
- Important22
- Board Meeting13
- Updates6
- PPTs5
Orchid Pharma partnered with Pharmasyntez JSC via a licensing and supply agreement for its novel antibiotic, Exblifep®, in Russia. Orchid will supply finished dosage, with Pharmasyntez holding commercialization rights. This presents a potential USD 178 million opportunity over 10 years.
Orchid Pharma's merger with Dhanuka Labs approved by NCLT, targeting combined sales of Rs. 1400-1500 Cr and EBITDA of Rs. 200-250 Cr. Shareholders receive 161 Orchid shares (FV Rs. 10) for 5 Dhanuka shares (FV Rs. 100). Appointed Date: April 1, 2024.
Orchid Pharma completed newspaper publications for its amalgamation scheme with Dhanuka Laboratories, as per NCLT instructions. This marks a key procedural step forward in the ongoing merger process.
Orchid Pharma has announced its 32nd Annual General Meeting virtually. Shareholders can participate and vote electronically on resolutions. Access to e-voting and meeting participation depends on their shareholding status.
Orchid Pharma's Alathur API facility has successfully completed a USFDA inspection, maintaining its status as the only USFDA-approved facility in India for Sterile Cephalosporins. The inspection, conducted from 10 to 18 February 2025, recorded seven minor observations, none related to data integrity, reflecting the facility's adherence to regulatory standards. This...